These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 15855526

  • 21. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.
    Sindelar G, Zhao X, Liew A, Dong Y, Lu T, Zhou J, Domagala J, Drlica K.
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3337-43. PubMed ID: 11083637
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K, Credito K, Pankuch GA, Lin G, Bozdogan B, McGhee P, Dewasse B, Choi DR, Ryu JM, Appelbaum PC.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [Abstract] [Full Text] [Related]

  • 25. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.
    Dalhoff A.
    Clin Infect Dis; 2001 Mar 15; 32 Suppl 1():S16-22. PubMed ID: 11249824
    [Abstract] [Full Text] [Related]

  • 26. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR, Malik M, Snyder M, Drlica K.
    J Mol Biol; 1996 May 17; 258(4):627-37. PubMed ID: 8636997
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J, Hooper DC.
    Antimicrob Agents Chemother; 2005 May 17; 49(5):1949-56. PubMed ID: 15855518
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
    Pereyre S, Renaudin H, Bébéar C, Bébéar CM.
    Antimicrob Agents Chemother; 2004 Aug 17; 48(8):3165-8. PubMed ID: 15273141
    [Abstract] [Full Text] [Related]

  • 32. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD.
    Antimicrob Agents Chemother; 2004 Jul 17; 48(7):2771-7. PubMed ID: 15215148
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [In vitro evaluation of lomefloxacin].
    Dette GA, Knothe H.
    Arzneimittelforschung; 1989 Aug 17; 39(8):832-5. PubMed ID: 2818672
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.
    Lewin CS, Morrissey I, Smith JT.
    Eur J Clin Microbiol Infect Dis; 1991 Apr 17; 10(4):240-8. PubMed ID: 1713846
    [Abstract] [Full Text] [Related]

  • 39. Antimycobacterial activities of novel fluoroquinolones.
    Senthilkumar P, Dinakaran M, Yogeeswari P, China A, Nagaraja V, Sriram D.
    Biomed Pharmacother; 2009 Jan 17; 63(1):27-35. PubMed ID: 18031974
    [Abstract] [Full Text] [Related]

  • 40. Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. smegmatis using theoretical molecular descriptors.
    Bagchi MC, Mills D, Basak SC.
    J Mol Model; 2007 Jan 17; 13(1):111-20. PubMed ID: 16932890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.